Merck KGaA

Equities

MRK

DE0006599905

Pharmaceuticals

Real-time Estimate Tradegate 14:55:11 17/07/2024 BST 5-day change 1st Jan Change
154.4 EUR +0.26% Intraday chart for Merck KGaA +3.35% +6.97%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Merck KGaA: share price down, analyst lowers target CF
MERCK KGAA : UBS lowers price target CF
UBS lowers target for Merck KGaA to 178 euros - 'Buy' DP
MERCK KGAA : UBS keeps its Buy rating ZD
Dawn Health and Merck Collaborate to Support Growth Disorders Care CI
Chemicals collective agreement: Bonus days for union members DP
Chemicals collective bargaining agreement: extra day for trade unionists DP
Chemical industry wage partners seek solution before the end of the peace period DP
German Stocks Fall Tuesday DJ
Market Update-Europe closes lower in a session marked by a wait-and-see attitude RE
Global markets live: UBS, Boeing, AT&T, Rivian, Nvidia, Tesla... Our Logo
MERCK KGAA : Barclays cuts its target price CF
MERCK KGAA : Gets a Neutral rating from Bernstein ZD
MERCK KGAA : failure in head and neck cancer trial CF
UBS reiterates Merck KGaA at 'Buy' - Target 186 euros DP
Next pharmaceutical study flop for Merck KGaA - share price collapses DP
European shares fall as Airbus hammers aerospace shares, tech slips RE
Merck KGaA shocks investors with end to cancer drug program DP
Merck KGaA Shares Drop After Canceled Late-Stage Cancer Drug Study DJ
FTSE 100 edges up but mood tetchy amid US tech woe AN
MERCK KGAA : UBS maintains a Buy rating ZD
Shares Frankfurt opening: Airbus weighs on Dax with profit warning DP
Merck KGaA shares plunge after cancer drug hopeful fails RE
European shares open lower on Airbus, tech drag RE
Barclays lowers target for Merck KGaA to 195 euros - 'Overweight' DP
Chart Merck KGaA
More charts
Merck KGaA is one of the world's leading pharmaceutical and chemical groups. Net sales break down by family of products as follows: - solutions and products for scientific and biotechnological research (44.2%); - pharmaceutical products (38.4%): prescription drugs for the treatment of diabetes, cancer, multiple sclerosis, infertility, cardiovascular disease, central nervous system disorders, inflammatory disorders, etc.; - performance materials for the electronics industry (17.4%): semiconductor materials, liquid crystals, pigments and additives, carbon-based organic materials, etc. Net sales are distributed geographically as follows: Germany (4.8%), Europe (24%), China (12.9%), Asia/Pacific (20.1%), the United States (26.8%), North America (1.6%), Latin America (6.3%), Middle East and Africa (3.5%).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
154 EUR
Average target price
183 EUR
Spread / Average Target
+18.83%
Consensus
  1. Stock Market
  2. Equities
  3. MRK Stock
  4. News Merck KGaA
  5. Merck Discontinues Xevinapant Trial